apatinib

Known as: 3-Pyridinecarboxamide, N-(4-(1-cyanocyclopentyl)phenyl)-2-((4-pyridinylmethyl)amino)-, methanesulfonate (1:1) 
An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2018
010203020102018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Currently, patients with radioiodine refractory differentiated thyroid cancer (RAIR-DTC) have limited treatment options. In this… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2016
Highly Cited
2016
PURPOSE There is currently no standard treatment strategy for patients with advanced metastatic gastric cancer experiencing… (More)
Is this relevant?
2016
2016
Tumor cells co-express vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFRs) that interact each other to support… (More)
Is this relevant?
2016
2016
Tumor cells produce vascular endothelial growth factor (VEGF) which can interact with membrane or cytoplasmic VEGF receptors… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
Apatinib is an oral, highly potent tyrosine-kinase inhibitor targeting VEGFR2. Phase I study showed the recommended dose of 750… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
PURPOSE Patients with metastatic gastric cancer (mGC) who do not respond to or who experience progression with second-line… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2013
2013
Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2(VEGFR-2). This study was… (More)
Is this relevant?
2013
2013
Apatinib is a new oral antiangiogenic molecule that inhibits vascular endothelial growth factor receptor-2. The present study… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 3
Is this relevant?
2012
2012
P-glycoprotein (P-gp, ABCB1) overexpression and enrichment of stem-like cells are linked to poor prognosis in tumor patients. In… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Apatinib, a small-molecule multitargeted tyrosine kinase inhibitor, is in phase III clinical trial for the treatment of patients… (More)
Is this relevant?